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Background and PurposeaaThere are no data regarding psychometrically validated, health-
related quality-of-life instruments designed specifically for patients with multiple sclerosis (MS) 
in Greece. Recently, the MS International Quality-of-Life questionnaire (MusiQoL), a multidi-
mensional, self-administered questionnaire, which is available in 14 languages (including Greek), 
has been validated using a large international sample. We investigated the validity and reliabi-
lity of the Greek version of the MusiQoL. 
MethodsaaConsecutive patients with different types and severities of MS were recruited from 
two tertiary-care centers in Greece. All patients completed the MusiQoL, the Short-Form-36 qu-
ality-of-life questionnaire (SF-36), and a symptom checklist at baseline and 21±7 days (mean± 
SD) later. Data regarding sociodemographic status, MS history, and functional outcome were also 
collected prospectively. Construct validity, internal consistency, reproducibility, and external con-
sistency were tested.   
ResultsaaA total of 92 patients was evaluated. The construct validity was confirmed in terms 
of satisfactory item-internal consistency correlations and scaling success (87.5-100%) of item-
discriminant validity. The dimensions of the MusiQoL exhibited high internal consistency (Cron-
bach’s alpha: 0.63-0.96), and reproducibility was satisfactory (intraclass correlation coeffici-
ents: 0.69-0.99). External validity testing indicated that the MusiQoL correlated significantly 
with all SF-36 dimension scores (Spearman’s correlation: 0.43-0.76). 
ConclusionsaaThe Greek version of the MusiQoL appears to be a valid and reliable instrument 
for measuring quality of life in Greek MS patients.  J Clin Neurol  2009;5:173-177
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Introduction 
 
Multiple sclerosis (MS) is a chronic progressive disease with 
multiple neurological and psychological impairments that lead 
to disability and require ongoing care.
1 The goal of evidence-
based medicine in the treatment of conditions such as MS, 
which produce morbidity but have a minimal impact on mor-
tality, is arguably to reduce the impact of the disease on pa-
tients’ lives and to ensure that any interventions do in fact 
improve their quality of life. These goals can only be achieved 
with input from the patients themselves. There is clear evid-
ence that MS has a significant negative impact on health-re-
lated quality of life (HRQoL).
2,3 The purpose of incorporating 
routine HRQoL data into clinical practice is to provide a com-
prehensive assessment of a patient’s health status from his or 
her perspective. However, the major challenge in developing 
an HRQoL questionnaire is to ensure that the subject’s per-
ceptions are accurately taken into account.
4 
Whilst the measured HRQoL is considered an important 
outcome in population health assessments evaluating treat-
ments and managing care,
5 there are virtually no data regard-
ing psychometrically validated HRQoL instruments designed 
specifically for patients with MS in Greece. Recently, the MS 
International Quality of Life questionnaire (MusiQoL), a 
multi-dimensional, self-administered questionnaire that is av-
ailable in 14 languages (including Greek), has been validated 
using a large international sample.
6 During this validation 
process, 1,992 patients were recruited from neurological de-  
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partments in 15 countries, including Greece. The validity and 
reliability of the Greek (translated) version of the MusiQoL 
were thus evaluated in this study using a sample of patients 
recruited from Greek tertiary-care centers. 
 
Methods 
 
Study population 
The patients enrolled in the MusiQoL validation study com-
prised a group of in- and outpatients who were being follow-
ed up in an international multicenter study. The patients were 
recruited between January 2004 and February 2005 from neu-
rological departments in 15 countries, including Greece. Two 
tertiary-care Greek university centers participated in this 
study (onein Athens, one in Thessaloniki). The details of this 
study have been presented elsewhere.
1 MS was diagnosed 
according to Poser
7 or MacDonald criteria.
8 The study was 
conducted in accordance with the Helsinki Declaration of 
Human Rights and all included patients gave their informed 
consent to participate. The main inclusion criteria were 1) MS 
diagnosed at least 6 months previously, 2) age >18 years, 3) 
provision of signed informed consent, and 4) Greek being the 
native language. The main exclusion criteria were 1) a diag-
nosis other than MS, 2) a history of dementia, 3) currently suf-
fering from a severe relapse, 4) inability to fill in the ques-
tionnaire unaided, and 5) withdrawal of consent. 
 
Patient evaluation 
All patients were evaluated at inclusion and then retested 
21±7 days (mean±SD) later. The self-administered survey 
materials (completed by the patients) included the MusiQoL 
and the Short-Form 36 (SF-36),
9 which is the most widely 
used general HRQoL scale in MS. The MusiQoL was com-
pleted during both the baseline and follow-up assessments. 
Two experienced MS neurologists
10,11 collected sociode-
mographic data and clinical history both related and unrelated 
to MS and its treatment. The neurologists also rated the fol-
lowing: Poser classification (mandatory), McDonald Classi-
fication (optional), the Expanded Disability Status Scale (ED-
SS),
12 the Kurtzke Functional Systems (KFS),
13 the Ambul-
ation Index for MS,
14 the Folstein Mini-Mental State Exami-
nation,
15 and a Clinical Global Impression of Severity (CGI).
16 
The CGI questionnaire was coded as mild, moderate, or se-
vere. At retest, patients completed the same questionnaire and 
one additional item assessing changes in their health status. 
The neurologists collected data on current care and again 
rated the EDSS, KFS, and CGI. They also compared the pa-
tient’s health status with that reported at inclusion (i.e., base-
line), and ranked it as worsened, remained stable, or improv-
ed. Finally, at retest all patients self-reported whether there 
was any evolution (e.g., no evolution, improvement, or dete-
rioration) in their clinical status. 
 
Statistical analyses 
Detailed statistical analyses testing the MusiQoL for internal 
structural validity, internal consistency, unidimensionality, re-
producibility, and external validity have been described else-
where.
6 In brief, item-internal consistency (IIC) was assessed 
by correlating each item with its scale, which was corrected 
for overlap (correlation of ≥0.4 recommended for supporting 
IIC). Item-discriminant validity (IDV) was assessed by de-
termining the extent to which items correlate more strongly 
with the dimensions they are hypothesized to represent than 
with the other dimensions. The internal consistency reliabi-
lity of each potential dimension scale was assessed by Cron-
bach’s alpha coefficient (alpha coefficient of at least 0.7 ex-
pected for each scale). The unidimensionality of each dimen-
sion was assessed using Rasch analyses. The scalability of 
each of the dimension scales was assessed by the pattern of 
item goodness-of-fit statistics (INFIT); INFIT values ranging 
between 0.7 and 1.2 ensure that all items of the scale tend to 
measure the same concept. Reproducibility was assessed as 
the test-retest reliability using intraclass correlation coeffici-
ents between the two successive assessments. To explore ex-
ternal validity, relationships were investigated between spe-
cific potential dimensions of the MusiQoL (e.g., symptoms 
and psychological well-being) and other instruments such as 
the SF-36, and corresponding Spearman’s correlation coeffi-
cients (r) were computed. Data analyses were performed us-
ing SPSS 11.0, MAP-R, LISREL, and WINSTEP software.
6 
 
Results 
 
A total of 92 subjects was recruited from the two Greek ter-
tiary-care centers. The baseline characteristics of the study 
population are presented in Table 1. All patients had clinical-
ly defined MS according to Poser criteria, and almost 80% 
of them had the relapsing-remitting clinical form. None of 
the patients had a clinically isolated syndrome according to 
the MS classification. 
The MusiQoL comprised 31 items describing the follow-
ing 9 dimensions: 
1) Activities of daily living (ADL), comprising eight items 
and accounting for 81.9% of the variance. 
2) Physical well-being (PWB), comprising four items and 
accounting for 9.1% of the variance. 
3) Symptoms, comprising three items and accounting for 
3.5% of the variance. 
4) Relationships with friends, comprising four items and 
accounting for 2.4% of the variance.  
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5) Relationships with family, comprising three items and 
accounting for 1.6% of the variance. 
6) Relationship with health-care system, comprising three 
items and accounting for 0.3% of the variance. 
7) Sentimental and sexual life, comprising two items and 
accounting for 0.7% of the variance. 
8) Coping, comprising two items and accounting for 0.5% 
of the variance. 
9) Rejection, comprising two items and accounting for 0% 
of the variance. 
The construct validity was confirmed in terms of satisfac-
tory IIC (Table 2) correlations and the scaling success of 
IDV (Table 2). The IIC correlations ranged between 0.42 and 
0.86 (with the exception of trait “being satisfied with your 
treatments”, for which the IIC correlation was 0.31) and IDV 
ranged from 87.5% to 100%. The Loevinger coefficient (H) 
analyses confirmed the unidimensionality of each dimension 
(H range: 0.41-0.88)(Table 3). 
Dimensions of the MusiQoL showed high internal consist-
ency, with Cronbach’s alpha coefficients ranging from 0.63 
to 0.96 (Table 4). Reproducibility was defined with regard to 
stable patients between test and retest according to either the 
answer of the patient or the assessment made by the physi-
cian using CGI. Overall, the reproducibility was satisfactory 
with intraclass correlation coefficients ranging from 0.69 to 
0.99 and from 0.72 to 0.99 for patients’ answers and physici-
Table 1. Baseline characteristics of the study population (n=192)
Variable  Value 
Gender (n, %)  
Male 60 (65%) 
Female 32 (35%) 
Age (mean±SD, years) 40.2±13.9 
Poser classification (n, %)  
Clinically defined MS  92 (100%) 
Laboratory defined MS  00 (0%) 
Clinically probable MS  00 (0%) 
Clinical form (n, %)  
Relapsing-remitting 74  (80.4%) 
Secondary progressive  16 (17.4%) 
Primary progressive  02 (2.2%) 
Clinically isolated syndrome  00 (0%) 
MS: multiple sclerosis. 
 
Table 2. Dimension scale characteristics 
Dimension (n of items)  IIC (min–max)  IDV (min–max) IDV (%)  MV (%)  Floor (%)  Ceiling (%) 
ADL (8) 0.62-0.86  -0.11-0.63  100.0  03.3  03.3  03.3 
PWB (4) 0.62-0.73  -0.03-0.53  100.0  0  01.1  02.2 
RFr (3) 0.55-0.72  -0.18-0.35  100.0  14.1  02.2  05.4 
SPT (4) 0.42-0.67  -0.03-0.43  096.9  02.2  00.0 25.0 
RF (3) 0.54-0.70  -0.08-0.34  100.0  04.3  01.1 28.3 
RHCS (3) 0.31-0.45  -0.07-0.63  087.5  04.3  00.0 25.0 
SSL (2) 0.84  -0.01-0.31  100.0  14.1  06.5 17.4 
COP (2) 0.86  -0.17-0.54 100.0  07.6 15.2 08.7 
REJ (2) 0.86  -0.17-0.65 100.0  19.6  04.3 31.5 
ADL: activities of daily living, PWB: physical well-being, RFr: relationships with friends, SPT: symptoms, RF: relationships with family, RHCS:
relationship with health-care system, SSL: sentimental and sexual life, COP: coping, REJ: rejection, IIC: item-internal consistency, IDV:
item-discriminant validity, MV: percentage of missing values, Floor: floor effect, Ceiling: ceiling effect.   
Table 3. Unidimensionality of each dimension 
Dimension (n of items)  H  INFIT 
ADL (8) 0.74  0.80-1.27 
PWB (4) 0.66  0.79-1.16 
RFr (3) 0.67  0.76-1.27 
SPT (4) 0.50  0.74-1.36 
RF (3) 0.52  0.72-1.24 
RHCS (3) 0.41  0.84-1.16 
SSL (2) 0.88  0.95-0.99 
COP (2) 0.78  0.97-0.99 
REJ (2) 0.83  0.97 
INFIT: pattern of item of goodness-of-fit statistics, H: Loevinger 
coefficient, ADL: activities of daily living, PWB: physical well-be-
ing, RFr: relationships with friends, SPT: symptoms, RF: relation-
ships with family, RHCS: relationship with health-care system, SSL:
sentimental and sexual life, COP: coping, REJ: rejection. 
 
Table 4. Internal consistency of each dimension 
Dimension (n of items)  Cronbach’s α 
ADL (8) 0.95 
PWB (4) 0.86 
RFr (3) 0.83 
SPT (4) 0.78 
RF (3) 0.73 
RHCS (3) 0.63 
SSL (2) 0.92 
COP (2) 0.86 
REJ (2) 0.89 
Cronbach’s α: Cronbach’s alpha coefficient. 
ADL: activities of daily living, PWB: physical well-being, RFr: re-
lationships with friends, SPT: symptoms, RF: relationships with fa-
mily, RHCS: relationship with health-care system, SSL: sentimen-
tal and sexual life, COP: coping, REJ: rejection. 
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ans’ assessments, respectively (Table 5). External validity 
testing indicated that the MusiQoL correlated significantly 
but moderately with all SF-36 dimension scores (Spearman’s 
correlation coefficient range: 0.43-0.76)(Table 6). Finally, 
ADL scores correlated strongly with SF-36 dimensions des-
cribing physical domains [physical functioning (r=0.85) and 
vitality (r=0.69)]. PWB also correlated strongly with the SF-
36 mental-health dimension covering psychological issues 
(r=0.68). 
 
Discussion 
 
Our analyses demonstrated the construct validity, internal con-
sistency, reproducibility, and external validity of the Greek 
version of the MusiQoL. This study confirmed the process of 
validation of the MusiQoL version translated into the Greek 
language and underscores its potential utility as an outcome 
measure in the clinical-trial setting. None of the previously 
available HRQoL instruments has been formally translated 
or validated in Greek patients with MS. 
Despite HRQoL questionnaires having become an import-
ant outcome parameter in the population health assessment 
of neurological disorders, very few HRQoL instruments have 
undergone a formal process of validation in the Greek langu-
age.
17,18 To the best of our knowledge no HRQoL question-
naire has been previously validated in MS patients in Greece. 
Our results for the construct validity, internal consistency, and 
reproducibility of the MusiQoL were similar to those of in-
ternational patient samples. They are also in line with previous 
differential item functioning analyses that have yielded satis-
factory results across countries.
6 The present findings, in com-
bination with those of the initial validation report,
6 thus indi-
cate a major strength of the MusiQoL; that is, the simultane-
ous process of validation in different countries around the 
world. Finally, they confirm that interviews with patients with 
MS contribute significantly to understanding patients with this 
condition,
19,20 and underline the importance of translating and 
validating HRQoL instruments in a patient’s native language 
in order to take into account national and ethnical disparities 
related to quality-of-life evaluations.
21,22 
The following limitations of the present study need to be 
acknowledged: 
1)  The sample was relatively small (n=92) and not prede-
termined. However, our analyses demonstrating the validity 
and reproducibility of the MusiQoL in this limited number of 
patients underscore the robustness of this instrument. 
2) Since no patients with clinically isolated syndrome and 
Table 5. Reproducibility of each dimension assessed by test-re-
test intraclass correlation coefficients (ICCs) by both patients (st-
ability defined as no change in general health according to the
answer of the patients) and physicians (stability defined as no
change in the Clinical Global Impression of Severity) 
Dimension (n of items)  Patient ICC  Physician ICC 
ADL (8) 0.99  0.98 
PWB (4) 0.89  0.87 
RFr (3) 0.91  0.89 
SPT (4) 0.69  0.72 
RF (3) 0.75  0.78 
RHCS (3) 0.98  0.98 
SSL (2) 0.94  0.96 
COP (2) 0.92  0.93 
REJ (2) 0.92  0.87 
Index 0.99  0.99 
Index: Ambulation Index for MS. 
ADL: activities of daily living, PWB: physical well-being, RFr: re-
lationships with friends, SPT: symptoms, RF: relationships with fa-
mily, RHCS: relationship with health-care system, SSL: sentimen-
tal and sexual life, COP: coping, REJ: rejection, MS: multiple sc-
lerosis. 
 
Table 6. Spearman’s correlations between MS International Quality-of-Life questionnaire (MusiQoL) and Short-Form 36 (SF-36) scores
SF-36 
MusiQoL 
PF  SF  RP  RE  MH  V  BP  GH 
ADL (8)  -0.85  0.74 0.77 0.61  0.46  0.69  0.32  0.48 
PWB (4)  -0.15  0.38 0.29 0.43  0.68  0.47  0.39  0.52 
RFr (3)  -0.02  0.14 0.07 0.07  0.27  0.21  0.07  0.19 
SPT (4)  -0.23  0.34 0.34 0.50  0.40  0.36  0.37  0.21 
RF (3)  -0.03  0.13 0.10 0.19  0.42  0.47  0.26  0.37 
RHCS (3)  -0.44  0.45 0.49 0.44  0.42  0.47  0.26  0.37 
SSL (2)  -0.24  0.40 0.33 0.34  0.38  0.34  0.15  0.33 
COP (2)  -0.01  0.31 0.24 0.35  0.56  0.31  0.17  0.31 
REJ (2)  -0.55  0.63 0.63 0.53  0.49  0.56  0.19  0.44 
Index  -0.43  0.69 0.66 0.73  0.76  0.70  0.17  0.49 
Index: Ambulation Index for MS. 
PF: physical functioning, SF: social functioning, RF: role, physical, RE: role, emotional, MH: mental health, V: vitality, BP: bodily pain, GH:
general health, ADL: activities of daily living, PWB: physical well-being, RFr: relationships with friends, SPT: symptoms, RF: relationships with 
family, RHCS: relationship with health-care system, SSL: sentimental and sexual life, COP: coping, REJ: rejection, MS: multiple sclerosis.    
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only two patients with primary progressive MS were includ-
ed in the present cohort, the potential applicability of the Mu-
siQoL in these specific subgroups cannot be inferred on the 
basis of the present results. 
3) The present study performed a retrospective analysis 
of prospectively collected data. Further research is required 
to test the strengths and weaknesses of the Greek version of 
the MusiQoL in a prospective fashion using a larger and 
more balanced (in terms of clinical subtypes of MS) sample. 
Indeed, our group plans to perform a prospective, independ-
ent study involving additional academic centers from Greece 
to evaluate the acceptability and compatibility of the Greek 
version of the MusiQoL in the clinical-practice setting. Dur-
ing that study we also plan to implement the MusiQoL in 
follow-up evaluations to explore and confirm its sensitivity 
to changes and to evaluate its potential applicability as a prog-
nostic tool. 
4) For the external validation of the MusiQoL we used the 
SF-36 questionnaire, which has not previously been validat-
ed in Greek patients with MS. 
5) Testing of the external validity of the MusiQoL scores 
showed significant but moderate correlations with those of 
the SF-36. Although the former results are encouraging, fur-
ther external validation studies utilizing some of the other 
available HRQoL instruments in MS
23,24 may be needed to 
explore the external validity of the MusiQoL in a more ro-
bust fashion. 
In conclusion, our findings indicate that the Greek version 
of the MusiQoL is a valid and reliable instrument with which 
to evaluate quality of life in Greek patients with MS. In the 
absence of any other validated HRQoL questionnaire in the 
Greek language, the MusiQoL appears to be a promising tool 
that can be readily applied as an outcome measure for evalu-
ating treatment or managing care in Greek patients with MS. 
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